[Lacosamide in treatment of patients with focal epilepsy and comorbid mental disorders]. / Primenenie lakosamida u patsientov s fokal'noi épilepsiei i komorbidnymi psikhicheskimi rasstroistvami.

In this article, the results of personal prospective observation of lacosamide (LCM) administration in 91 adults with epilepsy and comorbid mental disorders are presented. LCM was administered as a part of polytherapy for 80 patients at a dose of up to 400 mg/day and of monotherapy for 11 patients at a dose of up to 600 mg/day for up to 12 months. Clinical-psychopathological and experimental-psychological monitoring of patients' condition over time was carried out using the Mental Health Comprehensive Assessment Scale (MHCAS), the Global Clinical Impression scale (GCI). As a result, the majority of patients (58 people (63.7%)) achieved remission with good tolerability and positive changes in cognitive functions and emotional-volitional characteristics, confirming their stability after 1 year of LCM administration.

[Possibilities of treatment optimization in children and adolescents with epilepsy and disturbances of emotion and volition (disphoria)]. / Vozmozhnosti optimizatsii terapii detei i podrostkov, stradayushchikh epilepsiei s emotsional'no-volevymi narusheniyami (disforii).

AIM: To optimize the treatment of dysphoriain children and adolescents in regard to sex and disease severity. MATERIAL AND METHODS: Seventy children and adolescents (boys - 45, girls - 25), aged from 6 to 18 years, with different forms of epilepsy and emotion and dysphoric disturbances were studied using CPRS andGCIscales Depending on dysphoria severity, patients were stratified into three groups: mild (n=19 (27.1%), moderate (n=27 (38.6%)) and severe (n=24 (34.3%)). RESULTS AND CONCLUSION: Dysphoric disorders were significantly more prevalent in boys, hostility and aggression were characteristic of boys as well. These facts impactedtreatment options. Neuroleptics were more frequently used in boys (35.5%) compared to girls(16%).Mild dysphoria didn't require additional treatment besides AED in 78,4%. In 75% cases of moderate dysphoria,systemic treatment with neuroleptics for 6 months was necessary. One-time recommendations for neuroleptic treatment were made in all three groups with the prevalence in a groupof children with severe and moderate dysphoria.

[Therapy of psychotic schizophrenia spectrum disorders in adolescents].

OBJECTIVE: To assess the clinical efficacy, tolerability and safety of prolonged treatment with paliperidone in adolescents with the exacerbation of psychotic schizophrenia spectrum disorders. MATERIAL AND METHODS: Thirty-six adolescents at the age from 14 to 18 years with ICD-10 diagnosis F20-21, F25 were examined by clinical/psychopathological method (PANSS and CGI scale). The duration of the disease was from 1 to 3 years. The duration of the study was 12 months. RESULTS AND CONCLUSION: The efficacy and safety of prolonged use of paliperidone in a dose of 3 to 12 mg/day in adolescents with schizophrenia spectrum disorders were identified.